Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reina N Fuji

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Retina (Philadelphia, Pa.)|January 8, 2025
TRANSSCLERAL PARS PLANA CHOROID ABLATION USING THE IRIDEX LASER SYSTEM YIELDS IMPROVEMENTS FOR SURGICAL INSERTION OF THE PORT DELIVERY IMPLANT IN A MINIPIG MODELAmy Shelton, Melissa Schutten, Reina N Fuji, et al.
Toxicologic Pathology|November 7, 2022
Toxicologic Pathology Forum: A Roadmap for Building State-of-the-Art Digital Image Data Resources for Toxicologic Pathology in the Pharmaceutical IndustryXing-Yue Ge, Juergen Funk, Tom Albrecht, et al.
Molecular Cancer Therapeutics|October 8, 2009
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugatesBing Zheng, Reina N Fuji, Kristi Elkins, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 25, 2022
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidatesVidya Ramakrishnan, Christina Friedrich, Colleen Witt, et al.
JAMA Neurology|June 13, 2022
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical TrialEdmond Teng, Paul T Manser, Karen Pickthorn, et al.
Neurology|April 27, 2018
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer diseaseJeffrey L Cummings, Sharon Cohen, Christopher H van Dyck, et al.
Clinical Pharmacology and Therapeutics|January 22, 2022
Translational Approaches for Brain Delivery of Biologics via Cerebrospinal FluidShraddha S Sadekar, Mayumi Bowen, Hao Cai, et al.
Alzheimer'S Research & Therapy|September 21, 2018
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)Stephen Salloway, Lee A Honigberg, William Cho, et al.
Journal of Medicinal Chemistry|September 21, 2017
Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's DiseaseSnahel Patel, William J Meilandt, Rebecca I Erickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancerJagath R Junutula, Kelly M Flagella, Richard A Graham, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Retina (Philadelphia, Pa.)|January 8, 2025
TRANSSCLERAL PARS PLANA CHOROID ABLATION USING THE IRIDEX LASER SYSTEM YIELDS IMPROVEMENTS FOR SURGICAL INSERTION OF THE PORT DELIVERY IMPLANT IN A MINIPIG MODELAmy Shelton, Melissa Schutten, Reina N Fuji, et al.
Toxicologic Pathology|November 7, 2022
Toxicologic Pathology Forum: A Roadmap for Building State-of-the-Art Digital Image Data Resources for Toxicologic Pathology in the Pharmaceutical IndustryXing-Yue Ge, Juergen Funk, Tom Albrecht, et al.
Molecular Cancer Therapeutics|October 8, 2009
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugatesBing Zheng, Reina N Fuji, Kristi Elkins, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 25, 2022
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidatesVidya Ramakrishnan, Christina Friedrich, Colleen Witt, et al.
JAMA Neurology|June 13, 2022
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical TrialEdmond Teng, Paul T Manser, Karen Pickthorn, et al.
Neurology|April 27, 2018
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer diseaseJeffrey L Cummings, Sharon Cohen, Christopher H van Dyck, et al.
Clinical Pharmacology and Therapeutics|January 22, 2022
Translational Approaches for Brain Delivery of Biologics via Cerebrospinal FluidShraddha S Sadekar, Mayumi Bowen, Hao Cai, et al.
Alzheimer'S Research & Therapy|September 21, 2018
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)Stephen Salloway, Lee A Honigberg, William Cho, et al.
Journal of Medicinal Chemistry|September 21, 2017
Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's DiseaseSnahel Patel, William J Meilandt, Rebecca I Erickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancerJagath R Junutula, Kelly M Flagella, Richard A Graham, et al.
Pageof 3